Hackensack Meridian John Theurer Cancer Center | Strategic Alliance Partners

May 19, 2022

Results from the Thinking and Living with Cancer Study showed that the development of sleep disturbances during the early months of the COVID-19 pandemic increased symptoms of depression and anxiety among older women, but the findings did not differ between women who survived breast cancer and women without cancer.

May 16, 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

May 13, 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.

May 13, 2022

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

May 12, 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.

May 06, 2022

John Theurer Cancer Center at Hackensack University Medical Center in Hackensack has treated the first patient in the country with an investigational new drug for relapsed glioblastoma and other anaplastic gliomas.

May 03, 2022

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

April 21, 2022

Investigators from Hackensack University Medical Center’s John Theurer Cancer Center confirm that cryopreserved stem cells collected before a first stem cell transplant to treat multiple myeloma are just as viable and potent for use in a second "salvage" transplant 20 years later.

April 01, 2022

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.

March 15, 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

March 15, 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

March 10, 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

March 10, 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

March 09, 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

March 08, 2022

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

February 26, 2022

Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.

January 12, 2022

James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.

January 10, 2022

Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.

January 10, 2022

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

January 07, 2022

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.